Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
First Quarter 2018 Financial Results to be Announced May 8, 2018
Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials
CAMBRIDGE, Mass., May 01, 2018 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report the company’s first quarter 2018 financial results on Tuesday, May 8, 2018.
Epizyme also plans to host a conference call and webcast for investors on the morning of May 17, 2018 to discuss recent corporate updates and new tazemetostat clinical data that will be included in upcoming medical meeting abstracts. Details for this call will be provided in the company’s May 8 press release.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Contacts
Media:
Cheya Pope, Epizyme, Inc.
[email protected]
(617) 229-7561
Investors:
Jason Fredette, Epizyme, Inc.
[email protected]
(617) 500-0623
